Yoldaş İlktaç, HavvanurKızıltan, GülDevrim Lanpir, AslıOzansoy, MehmetGünal, Mehmet YalçınÖzmen Toğay, SineKeskin, İlknurÖzdemir, Ekrem MusaKılıç, Ülkan2022-05-272022-05-272022Yoldaş İlktaç, H., Kızıltan, G., Devrim Lanpir, A., Ozansoy, M., Günal, M. Y., Özmen Toğay, S. ... Kılıç, Ü. (2022). Combined therapy with probiotic VSL#3 and Omega-3 fatty acids attenuates colonic injury and inflammation in chronic DNBS-induced colitis in mice (vol 69, pg 135, 2021). Folia Biologica-Krakow, 70(1), 43-43. https://doi.org/10.3409/fb_70-1.050015-54971734-9168https://doi.org/10.3409/fb_70-1.05https://hdl.handle.net/20.500.12511/9474We published the abovementioned article about probiotic mixture VSL#3 on October 6, 2021. Since the product was named VSL#3 in our purchasing process in early 2016, it is referred to as VSL#3 in our article. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome® in the United States and Vivomixx® in Europe. The authors would like to apologise for any inconvenience caused.eninfo:eu-repo/semantics/openAccessOmega-3VSL#3Fatty AcidsDNBS-Induced ColitisOther701434310.3409/fb_70-1.05Q40007928844000052-s2.0-85130591657N/A